Abstract: #595: Sustained Viral Response Following Treatment with Direct Acting Antiviral Regimens Is Durable in More Than 6,600 Patients: Results of the Gilead Sustained Virologic Response Registry Study – Christian Schwab, et. al.
Summary: The 6,600 patients received various Gilead’s direct-acting antiviral drugs including ribavirin and pegylated interferon for a treatment period ranging from 24 weeks to 144 weeks. The patients who achieved a cure within three months were eligible for the study. Eight (0.1%) had a relapse, and 22 (0.3%) had reinfection. None of the patients with mild liver fibrosis (F0-F1) prior to treatment developed liver cancer. The patients who developed liver cancer based on their liver fibrosis prior to treatment was F2 (0.06%); F3 (0.25%), and F4 (0.58%). This showed a very good durable response with low liver cancer development rates.
Abstract: #602 Durability of Sustained Virologic Response and Liver Safety in Patients Treated with Glecaprevir/Pibrentasvir: A Long-Term Follow-up Study – Franco Felizarta,et. al.
Summary: In a follow-up of 792 days, all 87 patients (except 2) treated with glecaprevir/pibrentasvir (Maryret) maintained their sustained virologic response or cure. Reinfection was detected in one patient who relapsed before the post-SVR24 weeks and before this study ended.
Abstract: #681 Impact of Obesity on Treatment of Chronic Hepatitis C in Interferon-Free Direct-Acting Antiviral Era – KyDieu Tran, et. al.
Summary: A retrospective analysis conducted on patients with an average body mass index (BMI) of 30 kg/m2 (considered to be obese). A total of 168 patient records were found. All patients were treated with direct-acting antiviral (DAA) medications for 12 weeks. The cure rate was 95%. The authors concluded that obesity defined as BMI greater than 30kg/m2 does not have a negative effect on being cured with DAA medications.
Abstract: #715A (late breaker) Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1–6 Infection and Compensated Cirrhosis: The Expedition-8 Study – Robert S. Brown Jr., et. al.
Cohort 1 of 270 treatment-naïve patients treatment results were released that showed treatment with eight weeks of glecaprevir/pibrentasvir (Maryret) in hepatitis C (HCV) genotypes 1,2,4,5 and 6 patients with compensated cirrhosis achieved a 100% cure rate. Cohort B of treatment-naïve with compensated cirrhosis HCV genotype 3 patients is on going.
Abstract: #984 The Cost-Effectiveness of HCV Screening of Pregnant Women in the United States – Antoine Chaillon, et. al.
Summary: This study explored the cost-effectiveness to screen all pregnant women for hepatitis C (HCV) before giving birth to their babies. Based on their analysis, it was found that it is likely cost-effective to screen all pregnant women for HCV on a national level.
Note: Kentucky has passed legislation requiring screening of all pregnant women for HCV.
Share This Page